Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
Speaker 2: The Stock Movers Report, your roundup of companies making moves
Speaker 2: in the stock market, harnessing the power of Bloomberg data.
Speaker 1: Take a look at some of the stocks on the
Speaker 1: move today. We can do that with mister John Tucker, John, what.
Speaker 3: Do you got for us? I let's start with the
Speaker 3: country's largest meat packer, Tyson, once again soaring beast prices,
Speaker 3: denting sales, annual adjusted operating income of two point one
Speaker 3: billion to two point three billion for twenty twenty six.
Speaker 3: So that's they've lowered the range there. This weaker outlook
Speaker 3: suggests Tyson's efforts to reduce production capacity if you have
Speaker 3: to really have any significant impact, Tyson has ceased operations
Speaker 3: at the Nebraska beef plant. They cut output at a
Speaker 3: Texas facility. This was supposed to cool competition for cattle
Speaker 3: and improve their margins. Well, it hasn't shown up yet.
Speaker 3: The lower guidance also comes despite some recent glimmers of hope,
Speaker 3: including a plan resumption of cattle imports from Mexico. Also
Speaker 3: signs that ranchers are beginning to rebuild their herds, But
Speaker 3: again these developments they aren't likely to benefit packers for
Speaker 3: some time. Tyson is now expended to post an adjusted
Speaker 3: operating loss of five hundred million to six hundred and
Speaker 3: fifty million dollars for the year, deeper than some of
Speaker 3: the prior expectations. One Brice spot though.
Speaker 1: The Chickens Chicken, So Big Chicken.
Speaker 3: Astra Zeneca, of course in the news this morning exploring
Speaker 3: an acquisition of Bristol Meyers Squib of Princeton, New Jersey.
Speaker 3: According to our sources, potential mega deal could rank as
Speaker 3: the largest ever in Farman and you got to wonder, like,
Speaker 3: what are they going to say in the UK and
Speaker 3: what are the regulators going to say here? The companies
Speaker 3: have held early stage discussions about binding those, of course,
Speaker 3: are two cancer powerhouses. It would form the world's biggest
Speaker 3: drug maker with about one hundred and seven billion dollars
Speaker 3: in annual revenue. Bristol Meyers Squib could provide Astro with
Speaker 3: a bigger foothold in the US market. They're preparing for
Speaker 3: the loss of patent protection for some of their biggest products,
Speaker 3: including their blood thinner Eloquist. Last week, Bristol reported a
Speaker 3: quarterly sales of thirteen billion dollars, its highest ever you'll
Speaker 3: recall back in twenty twelve, Astra Zeneca fended off Peiser
Speaker 3: takeover attempt there and the UK government had to get
Speaker 3: involved over fears they'd lose one of their companies in
Speaker 3: the UKA.
Speaker 1: You know, you can't imagine these or at least I
Speaker 1: can't imagine these two companies getting regulatory row approval. But
Speaker 1: we're have an administration that is really open to some
Speaker 1: of these mega deals. So maybe the time is now.
Speaker 1: That's what we've been hearing from M and A bankers
Speaker 1: that if you want a mega now is the time.
Speaker 3: I don't know who would take this, the bankers behind
Speaker 3: this deal. I mean, you got to imagine like they're
Speaker 3: pressing for this because totally fee sure after the close
Speaker 3: of regular trading tomorrow Isabelle SpaceX.
Speaker 2: Yeah, I'm excited. I wonder if Elon mus will be there.
Speaker 3: He has better be here.
Speaker 1: That's the only reason people bought this doctor.
Speaker 3: Yeah. I don't think the financials are gonna tomorrow are
Speaker 3: going to matter as much as the commentary from from
Speaker 3: Elon during the call. Anyway, they'll be listening for progress
Speaker 3: with the Starship Mega Rocket, the availability of semiconductors, regulation
Speaker 3: and shortages, of AI Resources. As you know, a lot
Speaker 3: of institutional investors, they've they were sour on this to
Speaker 3: begin with because, in part because of the unprecedented control
Speaker 3: that Elon Musk has over SpaceX, they consider it a
Speaker 3: little too risky to hold must sits on over eighty
Speaker 3: percent of the voting rights companies chief executive, chief technical officer,
Speaker 3: and the chairman. It's a setup that one pension fund
Speaker 3: has called catastrophic. And then of course there's this just
Speaker 3: a few days after earnings, the lockup ends, so regardless
Speaker 3: of how good or bad the results are, at nine
Speaker 3: eleven million shares are subject to the lockup will be released.
Speaker 2: This Stock Movers report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 2: the Bloomberg Business app.